ArticlesArchiveAboutEditorial BoardAuthor Guidelines
Call for papersThe 2026 special issue on Climate & Health is open for submissions.Learn more
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En…
De Abullarade, Jezabel
Reconstruction of the forehead has been a challenge for many surgeons. Some use skin grafts, other microvascular flaps, but local flaps for coverage of forehead skin are still the cornerstone principle in providing the ideal skin color and tex ture. In this a…
Mark F. Naylor, David M. Thompson, Stan Lightfoot, Doris Mangiaracina Benbrook
New strategies are needed to treat cancers that do not respond to chemotherapy or resist chemotherapy after responding initially. The objective of this study was to evaluate non-cytotoxic drugs against two of these cancers, melanoma and ovarian cancer. Imiqui…
Christian Posch, Emmett Pinney, Susana Ortiz-Urda, Mayra Montes-Camacho, Gail K. Naughton
Unique characteristics in fetal development include scar-less wound healing and the paucity of tumor formation. Recent studies have demonstrated that the embryonic microenvironment can reverse melanoma cells to a benign melanocyte phenotype. We bioengineered…
Rong Bu, Abdul K. Siraj, Prashant Bavi, Asim Belgaumi, Shahab Uddin, Fowzan S. Alkuraya
Biallelic germline mutations in the mismatch repair genes, including MLH 1, MSH 2, MSH 6 or PMS 2, lead to a recess ive constitutional mismatch repair-deficiency (CMMR-D) syndrome characterized by early onset malignancies in chil dren and young adults. Becaus…
Sana Munaf Hawai, M. Al-Zayer, Mohammed M. Ali, Yuanjie Niu, A. Alawad, M. Aljofan, A. Aljarbou, S. Altuwaijri
Many studies have been done and many results have been established for studying cancers in human and the ways of treating it. However, one thing that remains relevant is the study model that is used to diagnose, cure or conclude treat ment methods for human c…
Otávio A. Curioni, Marcos B. de Carvalho, Rogério A. Dedivitis, Abrão Rapoport, Gilka J. F. Gattas
Aims: This study examined whether genetic polymorphisms of tobacco and alcohol-related metabolic genes such as GSTM 1, GSTT 1, GSTP 1, CYP 1 A 1, CYP 2 E 1 and DNA repair genes ( XRCC 1 194Trp, XRCC 1 399Gln, and XRCC 3 Met) contribute to the risk of developi…
Luís Arthur Flores Pelloso, Ismael Dale Cotrim Guerreiro da Silva, Naiara Côrrea Nogueira de Souza, Mihoko Yamamoto, Maria de Lourdes L. Ferrari Chauffaille
Acute Myeloid Leukemia (AML) is a group of genetically diverse hematopoietic malignancies arising from cell pro genitors developing in the myeloid pathway or from primitive stem cells. Genetic susceptibility of AML may account for an increased risk of AML due…
Cenk Yasa, Ozguc Takmaz, Ozlem Dural, Suleyman Engin Akhan
Endometrial cancer is the most common gynecologic malignancy in more developed countries. Most endometrial carcinomas cases are diagnosed at an early stage with a tumor confined to the uterine corpus. Although most patients are cured by surgery alone, about 1…
Luís Arthur Flores Pelloso, Sandra Serson Rohr, Mihoko Yamamoto, Maria de Lourdes L. Ferrari Chauffaille
We aimed to study the effect of elapsed time from AML diagnosis to treatment (TDT) on OS in a group of patients from public Hospital in Brazil. 41 AML (23 M, 18 F, 41 yrs, 18 - 84 yrs, from 2001 to 2004). There were 38 de novo AML and 3 secondary, median TDT…
Jianguo Chen, Weizhong Lu, Lianxin Wang, Yixin Zhang, Nengjin Wang, Yongsheng Chen, Jian Zhu, Hongwei Zheng, Jun Yang, Fei Chen
Background: Most of the reports on tumor relapse are recurrence of the same type of tumor after months to few years of a successful initial cancer treatment. It is generally unusual and unexpected that a different type of the second tumor occurs after several…
No articles in this issue.
JCT is an international journal dedicated to the latest advancements in cancer therapy. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in cancer related problems. All manuscripts must be prepared in En… All articles are open access under a CC BY 4.0 licence, with authors retaining copyright.
Authors submit their manuscript, metadata, and declarations through the portal. There is no submission fee.
The editorial office screens the manuscript for scope, completeness, and formatting before assigning a handling editor.
At least two independent reviewers evaluate the manuscript under single-blind review. Where revisions are required, authors respond point by point.
On acceptance the article processing charge is invoiced and the CC BY 4.0 copyright handover is signed.
The article is copyedited, typeset, and given a DOI, then publishes open access with a permanent link.
Manuscripts must be original and not under consideration elsewhere. Submit in Microsoft Word or LaTeX with figures at 300 dpi minimum. Structure research articles as Abstract, Introduction, Methods, Results, Discussion, and References.
Use the journal's numbered (Vancouver) reference style. Cite sources consecutively in the order they appear, and ensure every reference is complete and retrievable.
Declare all funding sources, conflicts of interest, and ethical approvals (including informed consent and animal-care statements where applicable).